Laboratorios Farmaceuticos ROVI SA
MAD:ROVI

Watchlist Manager
Laboratorios Farmaceuticos ROVI SA Logo
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Watchlist
Price: 63 EUR 1.86% Market Closed
Market Cap: 3.2B EUR
Have any thoughts about
Laboratorios Farmaceuticos ROVI SA?
Write Note

Gross Margin
Laboratorios Farmaceuticos ROVI SA

62.6%
Current
61%
Average
48.3%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
62.6%
=
Gross Profit
634.1m
/
Revenue
1B

Gross Margin Across Competitors

Country ES
Market Cap 3.3B EUR
Gross Margin
63%
Country JP
Market Cap 776 550.9T JPY
Gross Margin
-3%
Country US
Market Cap 710.5B USD
Gross Margin
81%
Country UK
Market Cap 440.4B GBP
Gross Margin
56%
Country DK
Market Cap 3.3T DKK
Gross Margin
85%
Country US
Market Cap 373.5B USD
Gross Margin
69%
Country US
Market Cap 251.1B USD
Gross Margin
77%
Country CH
Market Cap 202.7B CHF
Gross Margin
73%
Country CH
Market Cap 183.3B CHF
Gross Margin
75%
Country UK
Market Cap 162.4B GBP
Gross Margin
82%
Country IE
Market Cap 146B USD
Gross Margin
68%
No Stocks Found

Laboratorios Farmaceuticos ROVI SA
Glance View

Market Cap
3.3B EUR
Industry
Pharmaceuticals

Laboratorios Farmaceúticos Rovi SA engages in the research, development, manufacture, and marketing of small molecule and specialty biologic drugs. The company is headquartered in Madrid, Madrid and currently employs 1,751 full-time employees. The company went IPO on 2007-10-26. The Company’s main activities include the development and commercialization, nationwide and abroad, of medicines and drugs. Its products are structured into three fields: Diagnostic, which offers contrast mediums for use in magnetic resonance, ultrasound and X-ray diagnostics; Prescription, which distributes medicines under such brands as Hibor, Osseor, Hepadren, Pneumovax-23, Glufan, Corlentor, Exxiv, Calcio y Vitamina D3 Rovi and Absorcol, among others; and Over The Counter (OTC), which comprises the Perspirex, Enerzona, Dentimelo and ColdPack brands. The firm owns such fully consolidated subsidiaries as Gineladius SL, Frosst Iberica SA, Rovi Contract Manufacturing SL and Bertex Pharma GmbH, among others.

ROVI Intrinsic Value
83.93 EUR
Undervaluation 25%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
62.6%
=
Gross Profit
634.1m
/
Revenue
1B
What is the Gross Margin of Laboratorios Farmaceuticos ROVI SA?

Based on Laboratorios Farmaceuticos ROVI SA's most recent financial statements, the company has Gross Margin of 62.6%.